COVID-19 and ESKD, A Rapid Review

Ankur D Shah; Nathan Calabro-Kailukaitis

COVID-19 and ESKD, A Rapid Review

R I Med J (2013). 2020 Sep 4;103(8):29-33.

Authors

Ankur D Shah¹, Nathan Calabro-Kailukaitis²

Affiliations

¹ Alpert Medical School of Brown University, Providence, RI; Division of Kidney Disease and Hypertension, Rhode Island Hospital; Division of Nephrology, Medicine Service, Providence Veterans Affairs Medical Center, Providence, RI.
² Alpert Medical School of Brown University; Division of Kidney Disease and Hypertension, Rhode Island Hospital, Providence, RI.

PMID: 32900009

Abstract

In 2020, the COVID-19 pandemic has ravaged the world. Individuals with end-stage kidney disease (ESKD) are at higher risk due to impaired immunity, comorbid conditions, and dependence on travel to medical care settings. We review the salient features of COVID-19 in this population, including the risk of infection, disease course, changes in dialysis unit management, use of investigatory medications, access considerations, home dialysis, and capacity planning.

Keywords: COVID-19; coronavirus; dialysis; end-stage kidney disease.

Publication types

Review

MeSH terms

Betacoronavirus
COVID-19
Comorbidity
Coronavirus Infections* / epidemiology
Coronavirus Infections* / prevention & control
Disease Transmission, Infectious / prevention & control
Hemodialysis Units, Hospital / organization & administration*
Hemodialysis, Home / methods*
Humans
Infection Control / methods
Kidney Failure, Chronic* / epidemiology
Kidney Failure, Chronic* / therapy
Organizational Innovation
Pandemics* / prevention & control
Pneumonia, Viral* / epidemiology
Pneumonia, Viral* / prevention & control
Renal Dialysis / methods*
Risk Adjustment / methods*
SARS-CoV-2